Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00574834 · ClinicalTrials.gov registry record · Early Phase 1

Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes

A Early Phase 1 study, sponsored by University of Maryland, Baltimore.

Terminated
Registry status
Early Phase 1
Development phase
17
Enrollment target

NCT00574834: Clinical Trial Early Phase 1 study, sponsored by University of Maryland, Baltimore.

NCT00574834 is a Early Phase 1 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 17 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00574834, a Early Phase 1 study, was terminated before completion, sponsored by University of Maryland, Baltimore.

TERMINATED
Registry status
Early Phase 1
Development phase
17 participants
Enrollment target

Study Summary

The study will be focused on determining the integrated in-vivo mechanisms responsible for Ramipril's effects on delaying type 2 diabetes and restoring normal (blood sugar levels) glycemia in patients with impaired glucose tolerance. Hypothesis - Ramipril effects will delay the onset of type 2 diabetes and restore normal glycemia in patients with impaired glucose tolerance.

Primary Outcome

Measures of change in endogenous glucose production from baseline to final 30 minutes of clamp studies after 6 months of treatment.

Interventions

  • DRUG Ramipril
  • DRUG HCTZ-hydrochlorothiazide
  • DRUG Ramipril+HCTZ

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2007-03
Est. Completion 2014-08
Phase Early Phase 1
University of Maryland, Baltimore

560 total trials

Why NCT00574834 stopped before completion

NCT00574834 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (68% lower).

The record links to 0 conditions, and to 3 interventions - of which Ramipril is the first listed.

NCT00574834 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00574834 about?

NCT00574834 is a clinical study titled "Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes". The study will be focused on determining the integrated in-vivo mechanisms responsible for Ramipril's effects on delaying type 2 diabetes and restoring normal (blood sugar levels) glycemia in patients with impaired glucose tolerance. Hypothesis - Ramipril effects will delay the onset of type 2 diab...

What is the current status of trial NCT00574834?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2007-03. Estimated completion is 2014-08.

What interventions are being tested in trial NCT00574834?

The interventions under investigation include: Ramipril (DRUG), HCTZ-hydrochlorothiazide (DRUG), Ramipril+HCTZ (DRUG).

Who is sponsoring clinical trial NCT00574834?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00574834's enrollment target sits among peer trials

17 1350th of 2000 higher than 632 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00574834, the US trial registry maintained by the National Library of Medicine. NCT00574834 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.